Clinical Research Directory
Browse clinical research sites, groups, and studies.
RSV Burden in Hong Kong
Sponsor: Chinese University of Hong Kong
Summary
RSV infection causes significant mortality and morbidity in susceptible adults. There are many publications on the global RSV disease burden in infants and young children but data on adults are lacking with lots of knowledge gaps. Currently there is no established effective antiviral therapy for RSV. RSV vaccines have recently become available commercially but the Center for Health Protection (Hong Kong) has yet to discuss procurement of RSV vaccines for the high risk groups. Thus a prospective study to assess the disease burden of RSV infection in adults would be of great interest.
Official title: The Disease Burden of RSV Infection in Hong Kong
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
10000
Start Date
2026-03-01
Completion Date
2028-08-31
Last Updated
2026-01-08
Healthy Volunteers
No
Conditions
Interventions
Serial specimen sampling
Serial sampling of nasopharyngeal swab, saliva and sputum for RSV on day 3, 5, 7, 14, 28 (during hospitalization) for patients confirmed with RSV infection. Blood taking will be arranged on day 28 for serology purpose
Locations (1)
Chinese University of Hong Kong
Hong Kong, Hong Kong